The main therapeutic effect begins in the enteric nervous system, where peripheral μ-opioid receptor activation reduces acetylcholine release. This suppresses intestinal propulsion rather than simply changing stool composition. Slower transit leaves luminal fluid in contact with the mucosa longer, allowing greater water and electrolyte absorption and improving stool consistency.
Predominantly peripheral action is pharmacologically important because it concentrates the intended effect in the gastrointestinal tract. Loperamide and diphenoxylate act mainly at peripheral μ-opioid receptors, but excessive opioid activity can still produce serious toxicity. Therefore, their primarily peripheral profile does not remove the need to consider dose-related cardiac or central nervous system complications.
Outcome depends on the balance between reduced propulsion and excessive suppression of gut motility. Therapeutic slowing can decrease stool frequency, whereas excessive opioid activity may cause constipation or ileus. Dose-related toxicity may also include cardiac effects and central nervous system complications, making the intensity of opioid action a key safety variable.
They are symptomatic pharmacotherapy for selected acute or chronic diarrheal conditions, not a substitute for considering the cause of diarrhea. In practice, the possibility of an infectious cause must be assessed alongside contraindications and toxicity risks. This context helps determine whether slowing intestinal transit is appropriate for the patient’s presentation.
Improved stool frequency and consistency are the principal observable outcomes, but they should be interpreted as symptom control rather than proof that the underlying diarrheal cause has been corrected. This distinction is especially important in pharmacology because receptor-mediated slowing changes gastrointestinal function while infectious or other causes may remain.
Before treatment, clinicians should weigh the expected reduction in diarrhea against contraindications and the possibility of dose-related toxicity. This review is important because the same opioid-mediated reduction in propulsion that supports symptom relief can become excessive, producing constipation, ileus, cardiac effects, or central nervous system complications.